Could a common supplement fight scarring in rare immune disease lungs?
NCT ID NCT05593588
Summary
This study is testing if a supplement called Fisetin can help treat lung scarring in people with Common Variable Immunodeficiency (CVID), a rare immune disorder. Researchers will compare Fisetin to a placebo in 20 participants to see if it improves lung function, reduces lung scarring on scans, and enhances quality of life. The goal is to find a new treatment option to better control this serious complication of CVID.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMMON VARIABLE IMMUNODEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.